Alex's Lemonade Stand Celebrates 10 Years
In June of 2014, Alex's Lemonade Stand was on the Today show celebrating their 10 years of giving, featuring Don Small, Director of Pediatric Oncology.
ConKerr Cancer Foundation Supports Pediatric Oncology at Johns Hopkins
ConKerr Cancer Foundation, a "case for smiles" foundation that creates homemade pillowcases to children who have cancer and other life-threatening diseases, came to the pediatric oncology unit at the Johns Hopkins Children Center to make pillowcases for our patients.
Read more about their day at Johns Hopkins.
Kenneth Cooke, M.D., named Director of the Kimmel Cancer Center's Pediatric Bone Marrow Transplant Program
Dr. Kenneth Cooke has been named the Director of the Kimmel Cancer Center’s Pediatric Bone Marrow Transplantation Program. Prior to his appointment at Johns Hopkins, Dr. Cooke served as the Director of the Pediatric Blood and Marrow Transplantation Program at Rainbow Babies and Children’s Hospital and University Hospitals Case Medical Center in Ohio. He also was co-director of the Hematologic Disorders Program of the Case Comprehensive Cancer Center.
Dr. Cooke is nationally recognized in the field of transplantation immunology including bringing laboratory insights back to the clinic in the form of novel strategies designed to prevent or treat graft vs. host disease and lung complications. His translational research
efforts have been recognized by the Leukemia and Lymphoma Society and the American Society of Clinical Investigation. In addition, Dr. Cooke is interested in the delivery of care to the adolescent and young adult population.
Medical Degree: University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School
Residency: Children’s Hospital of Philadelphia
Fellowship: Children’s Hospital of Boston and Dana Farber Cancer Institute
For referrals and patient appointments: 443-287-6997
Grateful Patient Fundraising: A Young Philanthropist
On April 18, 2014 Kaitlyn Dorman, a twelve year old newly published songwriter, presented Dr. Raabe with a check to support his pediatric cancer research. Kaitlyn donated the royalties she received from the use of her original song in the 2014 Giant Triple Winner video, where Kaitlyn was featured as one of four Ambassadors.
Two years ago, Kaitlyn’s left arm became paralyzed and she could no longer play the piano. Kaitlyn was diagnosed with an inoperable cancerous brain tumor and put in the care of Dr. Eric Raabe at the Johns Hopkins Division of Pediatric Oncology. When her tumor was unresponsive to traditional treatment, she was put on an experimental therapy, offered only at 5 hospitals in the US. Today, Kaitlyn is back at school and learning to master the mandolin.
Outback Serves Lunch to Nurses in Appreciation
Outback Steakhouse provided lunch as a thank you to our many nurses in the Kimmel Cancer Center and the division of pediatric oncology to thank them for all the hard work and dedication to our patients and families as part of a nurses week celebration. As many as 400 nurses took part in the catered lunch sponsered by Outback. We extend a thank you, to our great partners at Outback who have a pledge to donate to childhood cancer research and provide supportive programs for the cancer center throughout the year.
Giant Food to Launch Triple Winner Program
Giant Food of Landover, Md. launched its tenth annual Triple Winner game on April 11 to benefit the Pediatric Oncology Division at the Johns Hopkins Kimmel Cancer Center and The Children’s Cancer Foundation, Inc.
From April 11 through July 20th shoppers at Giant Food stores can purchase for a $1, a scratch ticket and could be an instant winner of free store products or cash up to $10,000. Each year, four local children who are patients at the Kimmel Cancer Center are chosen to serve as Triple Winner ambassadors. This year’s ambassadors have several types of cancer, but they are not limited by their diagnoses. The treatment they receive enables them to continue to spend time with family, enjoy their hobbies, and make plans for the future.
- Gregory is an 11-year old who loves soccer, music, food and reading. This past summer, Gregory was well enough to attend Camp Sunrise—a week-long, overnight summer camp for children who have been diagnosed with or have survived cancer. In the fall, doctors agreed that he could return to school. Gregory has since resumed soccer and tennis, and will be trying out for baseball in the spring.
- 12-year old Kaitlin delights in playing the piano and learning new musical instruments. Soon after doctors found a tumor in her brain stem, Kaitlin became wheelchair bound and could not move her left arm. She was able to participate in a Johns Hopkins clinical trial and that treatment caused her tumor to shrink. Today, she is back to making the music everyone around her loves to hear.
- Eighteen-year old Quincy, first diagnosed with a rare small blue round cell tumor in early 2012, was referred to Johns Hopkins Division of Pediatric Oncology for radiation and a bone marrow transplant. He is now cancer-free and out of the hospital. He returned to school and in his free time, enjoys video games, swimming, and family gatherings.
- When Shauna, a six-year old fan of both the Baltimore Ravens and Miami Heat, was first diagnosed with renal cancer, she remained upbeat, entertaining hospital staff with dance moves and witty comments. Now, with her cancer treatment complete, Shauna is back in school, where she works hard and continues to be a self-motivated leader.
Since 2005, our Triple Winner program has raised $13.1 million for pediatric cancer research, making it one of the most successful cause-marketing programs in the nation. This year Giant has committed to raise another $1.6 million, in critical funds for the fight against children’s cancer.
Novel Mouse Model Could Further Understanding of Leukemias
Johns Hopkins Kimmel Cancer Center investigators have genetically engineered a new mouse that mimics a common form of leukemia in humans. Studying the model could lead to new understanding of the disease, they say.
The mice were bred to express a protein mutation within a gene known as FMS-like tyrosine kinase 3 (FLT3). The gene that forms FLT3's blueprint controls the development of healthy blood cells; mutations to it are seen in approximately a third of adult and pediatric cases of acute myeloid leukemia (AML).
Mutations in FLT3 are found in various regions of the gene, and the Johns Hopkins scientists designed the mouse to better understand the workings of the two most common ones in AML. They are ITD mutations, which cause a very aggressive form of the disease, and D835Y mutations, which cause a less aggressive form of the disease. The new mouse specifically expresses D835Y mutations. Mice bred to express ITD mutations were previously developed by the Johns Hopkins team.
To date, scientists have not understood why the ITD mutations cause more aggressive disease, says Donald Small, M.D., Ph.D., the Kyle Haydock Professor of Oncology and director of pediatric oncology at Johns Hopkins. Small led a team of researchers who originally cloned the FLT3 gene and linked it to leukemia a decade ago.
Patients with ITD mutations have only a 15 percent chance of a cure, Small says, compared with patients who have D835Y mutations, who have about a 50 percent chance of a cure. Studies comparing the new mice, containing D835Y mutations, with mice expressing ITD mutations provide “an ideal platform for dissecting the molecular mechanisms underlying the differences between the two mutations, and for drug screening against the two,” he says.
In work published online Nov. 18 in the journal Proceedings of the National Academy of Sciences, Small and his colleagues reported that FLT3 mutation types (either D835Y or ITD) are directly related to the aggressiveness of disease. In laboratory studies, the investigators found that mice with D835Y mutations, like people, develop much less aggressive disease than those with ITD mutations, both in disease severity and survival. D835Y mice lived an average of 1.5 times longer than those with ITD mutations – an average of 678 days versus 430 days. Those with the D835Y mutations also maintained a higher white blood-cell count and were not nearly as depleted in blood stem cells as those with the ITD mutations. The D835Y mutant mice also developed a broader spectrum of blood cancers, including lymphomas.
Investigators also tested the anticancer drugs Lestaurtinib (CEP-701) and sorafenib in the two types of mice. After 48 hours of treatment, the FLT3/D835Y mice responded to Lestaurtinib only, while the FLT3/ITD mice responded to both drugs.
“This new mouse model should enable us to further explore why patients with FLT3/ITD mutations have worse prognosis,” Small says. He and his team, he says, will be looking at the genes turned on and off by these mutations to further study molecular changes involved in leukemia development, and investigate pathways involved in other leukemias.
Coauthors of the study were Emily Bailey, Li Li, Amy S. Duffield, Hayley S. Ma, and David L. Huso. The work was supported by a National Institutes of Health (CA 090668 and CA 070970), the Leukemia & Lymphoma Society, and the Giant Food Pediatric Cancer Research Fund.
Link to the PNAS study
Proceeds from Ways to Live Forever Film Benefit Johns Hopkins Pediatric Oncology
Joining forces to beat childhood cancer and raise awareness, Johns Hopkins Pediatric Oncology has been selected by World Wide Motion Pictures Corporation to receive a portion of the proceeds from the film, Ways to Live Forever. Johns Hopkins, along with other cancer-related organizations will receive a portion of the box-office proceeds from the North American release of the film, Ways to Live Forever.
"The funds will be used for research on childhood cancers such as leukemia. Types of funding sources are even more critical in these days of federal cutbacks of research funding," said Donald Small, M.D., Ph.D., director of the pediatric oncology division at the Johns Hopkins Kimmel Cancer Center.
The film is based on the acclaimed British children's novel by Sally Nicholls. It tells the inspiring story of an ambitious 12-year-old named Sam and his best friend, Felix. Sam has leukemia and although the adults in his life don’t want him to dwell on it, Sam wants to know everything about his disease and death, a possibility he might face. In this poignant yet ultimately uplifting tale, Sam and his family face the immensity of an uncertain future with love, humor, and a touch of the unexpected.
Singer Savannah Outen Dedicates Song to Teen Cancer Patient
On March 18, YouTube sensation and Disney recording artist Savannah Outen will sing her newly-recorded song “Brave and True” to 16 year-old Bo Oliver, a cancer patient at the Johns Hopkins Kimmel Cancer Center.
Outen was paired with Oliver this past summer through Music is Medicine’s Donate a Song project. Outen wrote and recorded the song in Oliver’s honor. The song and music video will be sold to raise money for Johns Hopkins pediatric oncology research.
Music is Medicine Program Makes Dream Come True for Patient
Leora Friedman is 19 years old, a sophomore at Princeton, and the CEO of Music is Medicine, a youth-run organization that harnesses the power of music to make a difference in the lives of seriously-ill children.
What started out as a local service project in 2008 when Leora was 15, Music is Medicine has shot up to celebrity level status with “Donate a Song,” a project that empowers celebrity artists to use their talents to fund childhood disease research.